A Phase 1/2 interventional study of MEDI6469 Monotherapy and MEDI6469 Plus Tremelimumab in Advanced Solid Tumors and Aggressive B-cell Lymphomas, sponsored by MedImmune LLC. Terminated at 13 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-06-28.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.
1,432 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 48 is close to the median of 47 across 1,214 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted after MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
Biological: MEDI6469 Monotherapy
Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
Biological: MEDI6469 Monotherapy
Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
Biological: MEDI6469 Plus Tremelimumab
Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
Biological: MEDI6469 Plus Tremelimumab
Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
Biological: MEDI6469 Plus Durvalumab
Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
Biological: MEDI6469 Plus Durvalumab
Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
Biological: MEDI6469 Plus Durvalumab
Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m\^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
Biological: MEDI6469 plus Rituximab
Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
Biological: MEDI6469 plus Rituximab
single intravenous (IV) administration of MEDI6469
Drug pages: MEDI-6469 · Tremelimumab
MEDI6469 in combination with Tremelimumab
Drug pages: MEDI-6469 · Durvalumab
MEDI6469 in combination with Durvalumab
Drug pages: MEDI-6469 · Rituximab
MEDI6469 in combination with Rituximab
Maximum Tolerated Dose (MTD) of MEDI6469
The MTD was the highest dose within a cohort where no more than 1 out of 6 participants experienced dose-limiting toxicities (DLTs) or the highest protocol-defined dose for each agent in the absence of exceeding the MTD.
Time frame: From the first dose of study treatment through 28 days after the first dose (up to 28 days)
Number of Participants With DLTs
The DLT was any Grade 3 or higher treatment-related toxicity (including liver transaminase elevation higher than 8×upper limit of normal \[ULN\] or total bilirubin higher than 5×ULN; any \>=Grade 2 pneumonitis that did not resolve to \<=Grade 1 within 3 days) that occurred during the DLT time frame, and excluded the following: Grade 3 fatigue for less than or equal to (\<=) 7 days; Grade 3 endocrinopathy that was managed and the participant was asymptomatic; Grade 3 inflammatory reaction attributed to a local antitumor response that resolved to \<=Grade 1 within 30 days; concurrent vitiligo or alopecia of any grade; Grade 3 infusion-related reaction that resolved within 6 hours; and any more than or equal to (\>=) Grade 3 lymphopenia (unless clinically significant).
Time frame: From the first dose of study treatment through 28 days after the first dose (up to 28 days)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAEs were events present at baseline that worsened in intensity after administration of study treatment or events absent at baseline that emerged after administration of study treatment.
Time frame: From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year)
Number of Participants With Treatment-emergent Serious Adverse Events
A serious adverse event (SAE) was any AE that resulted in death, immediately life threatening, required (or prolonged) inpatient (or existing) hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect in offspring of the participant, or an important medical event that could jeopardize the participant or required medical intervention to prevent one of the outcomes listed above. Treatment-emergent SAEs were defined as SAEs present at baseline that worsened in intensity after administration of study treatment or SAEs absent at baseline that emerged after administration of study treatment.
Time frame: From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year)
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs
Laboratory evaluations of blood and urine samples were performed, including hematology (white blood cell \[WBC\] count with differential, red blood cell \[RBC\] count, hematocrit, hemoglobin, platelet count, mean corpuscular volume \[MCV\], and mean corpuscular hemoglobin concentration \[MCHC\]); serum chemistry (calcium, chloride, magnesium, creatinine, sodium, blood urea nitrogen \[BUN\], bicarbonate, glucose, aspartate transaminase \[AST\], total bilirubin, C-reactive protein, gamma-glutamyl transpeptidase \[GGT\], lactate dehydrogenase, uric acid, potassium, alanine transaminase \[ALT\], alkaline phosphatase, albumin, total protein, triglycerides, and cholesterol); urinalysis; and coagulation parameters.
Time frame: From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year)
Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as TEAEs
Vital signs examination included assessment of temperature, blood pressure, pulse rate, and respiratory rate. Physical examination included assessments of head, eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological, hematologic/lymphatic, and endocrine systems. The TEAEs related to these vital sign and physical examination abnormalities were reported.
Time frame: From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year)
Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as TEAEs
Electrocardiogram (ECG) parameters included atrial rate, PR interval, QRS duration, QTC interval, QT interval, and ventricular rate. All 12-lead ECGs performed during the study were obtained in triplicate. The TEAEs related to these ECG evaluation abnormalities were reported.
Time frame: From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year)
Best Overall Response (BOR)
Best overall response: Percentage (%) of participants with CR, partial response (PR), stable disease (SD), progressive disease (PD), or non-evaluable disease based on revised Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Per RECIST v1.1: CR-disappearance of all target/non-target lesions; PR at least a 30% decrease in sum of diameters of target lesions; SD-neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD-at least a 20% increase in sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. Per Cheson criteria: CR-disappearance of all evidence of disease; PR-regression of measurable disease and no new sites; SD-failure to attain CR/PR or PD; PD-any new lesion or increase by at least 50% of previously involved sites from nadir.
Time frame: From study entry until early termination (up to 1 year)
Objective Response Rate (ORR)
Objective response rate was defined as the percentage of participants with confirmed CR or confirmed PR according to revised RECIST v1.1 for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Confirmed CR and PR were those that persisted on repeat consecutive assessment \>= 4 weeks after the initial documentation of response. Tumor assessments according to revised RECIST v1.1 were defined as follows: CR - disappearance of all target/non-target lesions; PR - at least a 30% decrease in the sum of the diameters of target lesions. Tumor assessments according to Cheson criteria were defined as follows: CR - disappearance of all evidence of disease; PR- regression of measurable disease and no new sites.
Time frame: From study entry until early termination (up to 1 year)
Disease Control Rate
Disease control rate: Percentage of participants with CR, PR, or SD (if they maintained SD for \>= 8 weeks) according to revised RECIST v1.1 for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Tumor assessments according to revised RECIST v1.1 were defined as follows: CR -disappearance of all target/non-target lesions; PR - at least a 30% decrease in sum of diameters of target lesions; SD - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD - at least a 20% increase in sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. Tumor assessments according to Cheson criteria were defined as follows: CR- disappearance of all evidence of disease; PR - regression of measurable disease and no new sites; SD- failure to attain CR/PR or PD; PD- any new lesion or increase by at least 50% of previously involved sites from nadir.
Time frame: From study entry until early termination (up to 1 year)
Duration of Response (DOR)
Duration of response was the duration from the first documented objective response to the first documented PD or death due to any cause, whichever occurred first. Progression was based on revised RECIST v1.1 criteria for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. PD according to revised RECIST v1.1 was defined as: at least a 20% increase in the sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. PD per Cheson criteria was defined as: any new lesion or increase by at least 50% of previously involved sites from nadir.
Time frame: From Study entry until early termination (up to 1 year)
Progression-free Survival (PFS)
Progression-free survival was the duration measured from the start of study treatment until the first documentation of PD or death due to any cause, whichever occurred first. Progression was based on revised RECIST v1.1 criteria for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. PD according to revised RECIST v1.1 was defined as: at least a 20% increase in the sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. PD per Cheson criteria was defined as: any new lesion or increase by at least 50% of previously involved sites from nadir.
Time frame: From Study entry until early termination (up to 1 year)
Overall Survival (OS)
The OS was the duration from the start of study treatment until death due to any cause.
Time frame: From Study entry until early termination (up to 1 year)
Maximum Observed Serum Concentration (Cmax)
The pharmacokinetics (PK) parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
Time frame: MEDI6469 monotherapy: Days 1, 2, 3, 8, 15, and 29; MEDI6469 + tremelimumab or durvalumab: Days 1, 2, 3, 4, 8, 15, 29, and end of treatment (up to 1 year); MEDI6469 + rituximab: Days 3, 4, 8, 15, 29, 31, 59, every 28 days thereafter, and end of treatment
Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-inf)
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
Time frame: MEDI6469 monotherapy: Days 1, 2, 3, 8, 15, and 29; MEDI6469 + tremelimumab or durvalumab: Days 1, 2, 3, 4, 8, 15, 29, and end of treatment (up to 1 year); MEDI6469 + rituximab: Days 3, 4, 8, 15, 29, 31, 59, every 28 days thereafter, and end of treatment.
Systemic Clearance (CL)
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
Time frame: MEDI6469 monotherapy: Days 1, 2, 3, 8, 15, and 29; MEDI6469 + tremelimumab or durvalumab: Days 1, 2, 3, 4, 8, 15, 29, and end of treatment (up to 1 year); MEDI6469 + rituximab: Days 3, 4, 8, 15, 29, 31, 59, every 28 days thereafter, and end of treatment.
Terminal Phase Elimination Half-Life (T1/2)
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
Time frame: MEDI6469 monotherapy: Days 1, 2, 3, 8, 15, and 29; MEDI6469 + tremelimumab or durvalumab: Days 1, 2, 3, 4, 8, 15, 29, and end of treatment (up to 1 year); MEDI6469 + rituximab: Days 3, 4, 8, 15, 29, 31, 59, every 28 days thereafter, and end of treatment.
Number of Participants Positive for Human Anti-mouse Antibodies (HAMA)
The number of participants who developed detectable HAMA are presented. ImmuSTRIP® HAMA IgG ELISA Test System was used for detection, confirmation, and titration of HAMA in human serum with a HAMA positivity cut-off level of 74 nanogram per millilitre (ng/mL).
Time frame: All treatment arms: Days 8, 15, 29, and end of treatment (up to 1 year). Additionally for MEDI6469 + rituximab arm: Days 3, 31, 59, and every 28 days thereafter until end of treatment (up to 1 year)
A total of 58 participants were screened at 13 sites in the United States of America (USA).
| Milestone | MEDI6469 6 Milligram/Kilogram (mg/kg) | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 6 | 3 | 7 | 6 | 7 | 7 | 3 | 1 |
| Completed | 2 | 0 | 1 | 0 | 1 | 4 | 2 | 1 | 1 |
| Not completed | 6 | 6 | 2 | 7 | 5 | 3 | 5 | 2 | 0 |
| Withdrew: Death | 5 | 6 | 2 | 6 | 5 | 3 | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
The MTD was the highest dose within a cohort where no more than 1 out of 6 participants experienced dose-limiting toxicities (DLTs) or the highest protocol-defined dose for each agent in the absence of exceeding the MTD.
| milligram per kilogram (mg/kg) | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of MEDI6469 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
The DLT was any Grade 3 or higher treatment-related toxicity (including liver transaminase elevation higher than 8×upper limit of normal \[ULN\] or total bilirubin higher than 5×ULN; any \>=Grade 2 pneumonitis that did not resolve to \<=Grade 1 within 3 days) that occurred during the DLT time frame, and excluded the following: Grade 3 fatigue for less than or equal to (\<=) 7 days; Grade 3 endocrinopathy that was managed and the participant was asymptomatic; Grade 3 inflammatory reaction attributed to a local antitumor response that resolved to \<=Grade 1 within 30 days; concurrent vitiligo or alopecia of any grade; Grade 3 infusion-related reaction that resolved within 6 hours; and any more than or equal to (\>=) Grade 3 lymphopenia (unless clinically significant).
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With DLTs | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
An adverse event (AE) was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAEs were events present at baseline that worsened in intensity after administration of study treatment or events absent at baseline that emerged after administration of study treatment.
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 8 | 6 | 3 | 7 | 6 | 7 | 7 | 3 | 1 |
A serious adverse event (SAE) was any AE that resulted in death, immediately life threatening, required (or prolonged) inpatient (or existing) hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect in offspring of the participant, or an important medical event that could jeopardize the participant or required medical intervention to prevent one of the outcomes listed above. Treatment-emergent SAEs were defined as SAEs present at baseline that worsened in intensity after administration of study treatment or SAEs absent at baseline that emerged after administration of study treatment.
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events | 4 | 3 | 1 | 5 | 3 | 3 | 3 | 2 | 0 |
Laboratory evaluations of blood and urine samples were performed, including hematology (white blood cell \[WBC\] count with differential, red blood cell \[RBC\] count, hematocrit, hemoglobin, platelet count, mean corpuscular volume \[MCV\], and mean corpuscular hemoglobin concentration \[MCHC\]); serum chemistry (calcium, chloride, magnesium, creatinine, sodium, blood urea nitrogen \[BUN\], bicarbonate, glucose, aspartate transaminase \[AST\], total bilirubin, C-reactive protein, gamma-glutamyl transpeptidase \[GGT\], lactate dehydrogenase, uric acid, potassium, alanine transaminase \[ALT\], alkaline phosphatase, albumin, total protein, triglycerides, and cholesterol); urinalysis; and coagulation parameters.
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 1 | 1 |
| Neutrophil count increased | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphopenia | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Blood iron decreased | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hemoglobin decreased | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelet count decreased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Thrombocytopenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypernatremia | 1 | 1 | 1 | 3 | 2 | 0 | 2 | 0 | 0 |
| Hypokalemia | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 |
| Aspartate aminotransferase increased | 1 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 |
| Hypomagnesemia | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 | 0 |
| Blood alkaline phosphatase increased | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Hyperglycemia | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Alanine aminotransferase increased | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Blood creatinine increased | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 |
| Gamma-glutamyltransferase increased | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Hypercalcemia | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperkalemia | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Hyperuricemia | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Blood bilirubin increased | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Hypophosphatemia | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood cholesterol increased | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood glucose increased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood thyroid stimulating hormone increased | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypocalcemia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypothyroidism | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Iron deficiency | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liver function test increased | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Tri-iodothyronine free decreased | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Troponin increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Thyroxine free decreased | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hematuria | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activated partial thromboplastin time prolonged | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
Vital signs examination included assessment of temperature, blood pressure, pulse rate, and respiratory rate. Physical examination included assessments of head, eyes, ears, nose, throat, respiratory, cardiovascular, gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological, hematologic/lymphatic, and endocrine systems. The TEAEs related to these vital sign and physical examination abnormalities were reported.
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Pyrexia | 1 | 2 | 2 | 2 | 0 | 3 | 2 | 0 | 0 |
| Dyspnea | 0 | 2 | 1 | 0 | 1 | 2 | 1 | 0 | 1 |
| Hypotension | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Sinus tachycardia | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Dyspnea exertional | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Tachycardia | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Bradycardia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypertension | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypoxia | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Wheezing | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Electrocardiogram (ECG) parameters included atrial rate, PR interval, QRS duration, QTC interval, QT interval, and ventricular rate. All 12-lead ECGs performed during the study were obtained in triplicate. The TEAEs related to these ECG evaluation abnormalities were reported.
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as TEAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Best overall response: Percentage (%) of participants with CR, partial response (PR), stable disease (SD), progressive disease (PD), or non-evaluable disease based on revised Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Per RECIST v1.1: CR-disappearance of all target/non-target lesions; PR at least a 30% decrease in sum of diameters of target lesions; SD-neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD-at least a 20% increase in sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. Per Cheson criteria: CR-disappearance of all evidence of disease; PR-regression of measurable disease and no new sites; SD-failure to attain CR/PR or PD; PD-any new lesion or increase by at least 50% of previously involved sites from nadir.
| Percentage of participants | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 |
| SD | 12.5 | 0 | 33.3 | 28.6 | 33.3 | 14.3 | 0 | 33.3 | 100.0 |
| PD | 50.0 | 33.3 | 66.7 | 42.9 | 50.0 | 42.9 | 100.0 | 66.7 | 0 |
| NE | 37.5 | 66.7 | 0 | 28.6 | 0 | 42.9 | 0 | 0 | 0 |
Objective response rate was defined as the percentage of participants with confirmed CR or confirmed PR according to revised RECIST v1.1 for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Confirmed CR and PR were those that persisted on repeat consecutive assessment \>= 4 weeks after the initial documentation of response. Tumor assessments according to revised RECIST v1.1 were defined as follows: CR - disappearance of all target/non-target lesions; PR - at least a 30% decrease in the sum of the diameters of target lesions. Tumor assessments according to Cheson criteria were defined as follows: CR - disappearance of all evidence of disease; PR- regression of measurable disease and no new sites.
| Percentage of participants | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 |
Disease control rate: Percentage of participants with CR, PR, or SD (if they maintained SD for \>= 8 weeks) according to revised RECIST v1.1 for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. Tumor assessments according to revised RECIST v1.1 were defined as follows: CR -disappearance of all target/non-target lesions; PR - at least a 30% decrease in sum of diameters of target lesions; SD - neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; PD - at least a 20% increase in sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. Tumor assessments according to Cheson criteria were defined as follows: CR- disappearance of all evidence of disease; PR - regression of measurable disease and no new sites; SD- failure to attain CR/PR or PD; PD- any new lesion or increase by at least 50% of previously involved sites from nadir.
| Percentage of participants | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Disease Control Rate | 12.5 | 0 | 33.3 | 28.6 | 50.0 | 14.3 | 0 | 33.3 | 100.0 |
Duration of response was the duration from the first documented objective response to the first documented PD or death due to any cause, whichever occurred first. Progression was based on revised RECIST v1.1 criteria for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. PD according to revised RECIST v1.1 was defined as: at least a 20% increase in the sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. PD per Cheson criteria was defined as: any new lesion or increase by at least 50% of previously involved sites from nadir.
| Days | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) | — | — | — | — | 368 | — | — | — | — |
Progression-free survival was the duration measured from the start of study treatment until the first documentation of PD or death due to any cause, whichever occurred first. Progression was based on revised RECIST v1.1 criteria for monotherapy and combination tremelimumab and durvalumab arms, and Cheson criteria for combination rituximuab arms. PD according to revised RECIST v1.1 was defined as: at least a 20% increase in the sum of diameters of target lesions, or a substantial worsening in a non-target lesion, or the appearance of new lesions. PD per Cheson criteria was defined as: any new lesion or increase by at least 50% of previously involved sites from nadir.
| Months | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 1.8 (0.9 to 3.5) | 1.8 (1.8 to 1.8) | 1.9 (1.8 to 6.4) | 2.8 (0.7 to 6.7) | 5.6 (1.0 to 17.8) | 1.8 (1.0 to 6.4) | 1.4 (1.0 to 1.8) | 1.0 (0.9 to NA) | 5.4 (NA to NA) |
The OS was the duration from the start of study treatment until death due to any cause.
| Months | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 6.1 (0.9 to NA) | 6.5 (1.8 to 10.7) | 13.1 (11.2 to NA) | 6.7 (2.0 to 12.5) | 11.2 (1.2 to 17.8) | NA (1.0 to NA) | 2.9 (2.5 to NA) | 3.3 (1.7 to NA) | NA (NA to NA) |
The pharmacokinetics (PK) parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
| microgram per milliliter | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 133.76 ± 34.87 | 188.87 ± 59.88 | 49.00 ± 1.29 | 43.67 ± 7.99 | 40.21 ± 8.20 | 42.10 ± 6.63 | 234.91 ± 56.05 | 31.68 ± 5.06 | 289.40 ± NA |
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
| day*microgram per milliliter | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-inf) | 556.92 ± 166.95 | 873.16 ± 328.74 | 169.34 ± 18.15 | 183.09 ± 26.27 | 144.91 ± 33.07 | 169.65 ± 45.98 | 998.25 ± 400.12 | 145.55 ± 16.86 | 1619.73 ± NA |
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
| liter per day | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Systemic Clearance (CL) | 0.81 ± 0.224 | 0.84 ± 0.246 | 1.02 ± 0.155 | 0.89 ± 0.132 | 1.04 ± 0.288 | 1.0 ± 0.266 | 0.84 ± 0.173 | 1.11 ± 0.188 | 0.77 ± NA |
The PK parameter was estimated using the non-compartmental analysis methods, based on the participant serum concentration-time data. The concentration-time curve was the result of blood sampling at specified time points and its measured concentration of MEDI6469
| Day | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Terminal Phase Elimination Half-Life (T1/2) | 2.83 ± 0.83 | 3.20 ± 1.23 | 1.56 ± 0.04 | 2.86 ± 0.68 | 2.73 ± 0.65 | 3.30 ± 0.68 | 2.98 ± 1.06 | 3.75 ± 1.03 | 4.19 ± NA |
The number of participants who developed detectable HAMA are presented. ImmuSTRIP® HAMA IgG ELISA Test System was used for detection, confirmation, and titration of HAMA in human serum with a HAMA positivity cut-off level of 74 nanogram per millilitre (ng/mL).
| Participant | MEDI6469 6 mg/kg | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+ Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg + Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Positive for Human Anti-mouse Antibodies (HAMA) | 5 | 4 | 3 | 6 | 5 | 6 | 4 | 1 | 0 |
Collected over From study treatment administration (Day 1) to 90 days after the last dose of study treatment or early termination of study (up to 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEDI6469 6 Milligram/Kilogram (mg/kg) | — | 4/8 (50%) | 6/8 (75%) |
| MEDI6469 10 mg/kg | — | 3/6 (50%) | 6/6 (100%) |
| MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | — | 1/3 (33.3%) | 3/3 (100%) |
| MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | — | 5/7 (71.4%) | 7/7 (100%) |
| MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | — | 3/6 (50%) | 6/6 (100%) |
| MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | — | 3/7 (42.9%) | 7/7 (100%) |
| MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | — | 3/7 (42.9%) | 7/7 (100%) |
| MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | — | 2/3 (66.7%) | 3/3 (100%) |
| MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 | — | 0/1 (0%) | 1/1 (100%) |
| Event | MEDI6469 6 Milligram/Kilogram (mg/kg) | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/8 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| VomitingGastrointestinal disorders | 0/8 | 0/6 | 1/3 | 1/7 | 0/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| AstheniaGeneral disorders | 0/8 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 1/7 | 1/3 | 0/1 |
| GastroenteritisInfections and infestations | 0/8 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| Wound infectionInfections and infestations | 0/8 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/7 | 1/3 | 0/1 |
| DehydrationMetabolism and nutrition disorders | 0/8 | 1/6 | 1/3 | 0/7 | 1/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/8 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/7 | 1/3 | 0/1 |
| MalnutritionMetabolism and nutrition disorders | 0/8 | 0/6 | 1/3 | 0/7 | 0/6 | 0/7 | 0/7 | 0/3 | 0/1 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/8 | 0/6 | 0/3 | 0/7 | 0/6 | 0/7 | 0/7 | 1/3 | 0/1 |
| Event | MEDI6469 6 Milligram/Kilogram (mg/kg) | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/8 | 2/6 | 2/3 | 2/7 | 1/6 | 1/7 | 2/7 | 1/3 | 1/1 |
| FatigueGeneral disorders | 3/8 | 2/6 | 3/3 | 4/7 | 4/6 | 3/7 | 3/7 | 1/3 | 1/1 |
| Oedema peripheralGeneral disorders | 1/8 | 0/6 | 0/3 | 2/7 | 2/6 | 1/7 | 1/7 | 1/3 | 1/1 |
| Aspartate aminotransferase increasedInvestigations | 1/8 | 0/6 | 0/3 | 3/7 | 1/6 | 1/7 | 1/7 | 0/3 | 1/1 |
| Blood creatinine increasedInvestigations | 0/8 | 0/6 | 0/3 | 1/7 | 2/6 | 0/7 | 0/7 | 0/3 | 1/1 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 3/6 | 1/3 | 3/7 | 2/6 | 0/7 | 0/7 | 0/3 | 1/1 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/8 | 0/6 | 0/3 | 0/7 | 1/6 | 0/7 | 0/7 | 1/3 | 1/1 |
| DizzinessNervous system disorders | 1/8 | 1/6 | 1/3 | 0/7 | 2/6 | 2/7 | 0/7 | 0/3 | 1/1 |
| HeadacheNervous system disorders | 3/8 | 0/6 | 0/3 | 0/7 | 3/6 | 1/7 | 2/7 | 0/3 | 1/1 |
| AnxietyPsychiatric disorders | 0/8 | 1/6 | 0/3 | 1/7 | 0/6 | 0/7 | 0/7 | 1/3 | 1/1 |
| Age, Continuous(Years) | MEDI6469 6 Milligram/Kilogram (mg/kg) | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.5 ± 12.6 | 63.8 ± 8.9 | 48.0 ± 6.9 | 61.3 ± 8.7 | 57.5 ± 19.4 | 66.6 ± 14.5 | 62.6 ± 9.1 | 70.3 ± 4.6 | 73.0 ± NA | 61.9 ± 12.2 |
| Sex: Female, Male(Participants) | MEDI6469 6 Milligram/Kilogram (mg/kg) | MEDI6469 10 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 3 mg/kg | MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg | MEDI6469 2 mg/kg+Durvalumab 3 mg/kg | MEDI6469 2 mg/kg+Durvalumab 10 mg/kg | MEDI6469 10 mg/kg+Durvalumab 10 mg/kg | MEDI6469 2 mg/kg+Rituximab 375 mg/m^2 | MEDI6469 10 mg/kg+Rituximab 375 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 3 | 2 | 2 | 3 | 1 | 3 | 1 | 0 | 20 |
| Male | 3 | 3 | 1 | 5 | 3 | 6 | 4 | 2 | 1 | 28 |
Ran from Aug 2014 to primary completion in Apr 2016, 19 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MEDI-6469 · Tremelimumab · Durvalumab · Rituximab
Lymphoma, Large B-Cell, Diffuse →